Psilocybin shows promise in early study for anorexia treatment

A recent study published in *Scientific American* reports that a single dose of psilocybin, the psychoactive compound found in certain mushrooms, may accelerate recovery in individuals with anorexia nervosa. Researchers administered the drug to a small cohort of patients in a controlled setting and observed significant improvements in eating behaviors and psychological well‑being within weeks of treatment. The study’s authors emphasize that the findings are preliminary but suggest that psilocybin could serve as a catalyst for traditional therapy, potentially reducing the time needed for patients to achieve stable weight and healthier attitudes toward food.

The research team conducted the trials in a clinical environment with rigorous safety protocols, monitoring participants for adverse effects and providing psychological support throughout the process. Participants reported increased openness to change and a reduction in the obsessive thoughts that often accompany anorexia. While the sample size was limited and the study was not designed as a definitive clinical trial, the early results align with a growing body of evidence indicating that psychedelic-assisted therapy may offer benefits for eating disorders that are resistant to conventional treatments.

If these preliminary outcomes are confirmed in larger, randomized studies, psilocybin could become a valuable adjunct to existing therapeutic approaches for anorexia nervosa. The authors call for further research to establish optimal dosing regimens, long‑term efficacy, and safety profiles before the treatment can be widely adopted. For now, the study adds to a cautious but hopeful conversation about integrating psychedelic substances into mental‑health care.